Matthew Link Sells 5,042 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Matthew Link sold 5,042 shares of Sight Sciences stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $2.31, for a total transaction of $11,647.02. Following the completion of the sale, the insider now owns 830,551 shares of the company’s stock, valued at $1,918,572.81. This trade represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Sight Sciences Trading Up 3.1 %

Shares of NASDAQ:SGHT opened at $2.30 on Friday. Sight Sciences, Inc. has a 52-week low of $2.04 and a 52-week high of $8.45. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. The company has a market cap of $118.07 million, a P/E ratio of -2.25 and a beta of 2.46. The stock’s 50-day moving average is $2.67 and its 200-day moving average is $3.84.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The business had revenue of $19.07 million during the quarter, compared to the consensus estimate of $18.98 million. During the same period in the prior year, the firm earned ($0.22) earnings per share. Equities research analysts predict that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Hedge Funds Weigh In On Sight Sciences

Several large investors have recently bought and sold shares of the stock. ProShare Advisors LLC acquired a new stake in Sight Sciences in the 4th quarter worth $36,000. Dynamic Technology Lab Private Ltd acquired a new stake in Sight Sciences during the fourth quarter worth about $40,000. Arkadios Wealth Advisors bought a new position in Sight Sciences during the fourth quarter valued at about $47,000. WealthTrust Asset Management LLC acquired a new position in Sight Sciences in the 4th quarter valued at approximately $48,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Sight Sciences in the 4th quarter worth approximately $50,000. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Lake Street Capital cut their price target on shares of Sight Sciences from $3.00 to $2.50 and set a “hold” rating on the stock in a report on Thursday, March 6th. Stifel Nicolaus lowered their target price on shares of Sight Sciences from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, March 6th. UBS Group reduced their price target on Sight Sciences from $5.50 to $5.00 and set a “buy” rating for the company in a research report on Monday, January 27th. Piper Sandler decreased their price target on Sight Sciences from $5.50 to $3.50 and set a “neutral” rating for the company in a research note on Thursday, March 6th. Finally, Citigroup cut their price objective on Sight Sciences from $4.60 to $3.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $3.83.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.